GGrantIndex
Sort

25,944 grants matching neurodegeneration

Introducing Cellular Aging in Human iPS Cells to Investigate Alzheimer Pathogenesis

$2,093,750
Hong Zhang · Univ Of Massachusetts Med Sch Worcester · RF1 · FY2017 · AG

Optogenetics and Transgenic Technology Core

$2,092,870
Brandon Harvey · National Institute On Drug Abuse · ZIC · FY2016 · DA

Investigating Pathways from Adverse Pregnancy Outcomes to Alzheimer's Disease and Related Dementias: the nuMoM2b-Brain Study

$2,090,311
Eliza C Miller · Columbia University Health Sciences · R01 · FY2024 · AG

ASYMMETRIC NEURODEGENERATION AND LANGUAGE IN PRIMARY PROGRESSIVE APHASIA

$2,089,742
Marek-Marsel M Mesulam · Northwestern University At Chicago · R01 · FY2022 · AG

Procurement and Characterization of Postmortem Brain Tissue

$2,089,295
Joel Kleinman · National Institute Of Mental Health · Z01 · FY2008 · MH

Roles Of Brain Neuroimmune System In Neurodegeneration

$2,089,144
Jau-Shyong Shyong Hong · National Institute Of Environmental Health Sciences · ZIA · FY2016 · ES

Traumatic Brain Injury and Repetitive Head Impacts: Contributions to AD/ADRD and CTE Neuropathology and Resulting Clinical Syndromes

$2,086,962
Ann Carolyn McKee · Boston University Medical Campus · U54 · FY2019 · NS

SOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALING

$2,086,796
Kenneth D. Tew · Medical University Of South Carolina · P20 · FY2013 · GM

Einstein Aging Study

$2,086,773
Richard B. Lipton · Albert Einstein College Of Medicine · P01 · FY2011 · AG

Neuroimaging and clinical Endpoints With High-dimensional analysis Of Pathological Endophenotypes in TBI (NEW-HOPE-TBI)

$2,085,613
Christopher D Keene · University Of Washington · U01 · FY2025 · NS

Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

$2,085,362
Brian Jason Wainger · Massachusetts General Hospital · RF1 · FY2023 · NS

Ex Vivo Imaging of the Aging Brain to Discover Morphology/Pathology Associations

$2,077,693
Paul A. Yushkevich · University Of Pennsylvania · RF1 · FY2023 · AG

Organization and Dynamics of Endomembrane Pathways and Organelles

$2,075,453
Jennifer Lippincott-Schwartz · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2011 · HD

Genomic regulation of immune response in neurodegeneration in mice

$2,074,665
Han-Yu Shih · National Eye Institute · ZIA · FY2024 · EY

Roles Of Brain Neuroimmune System In Neurodegeneration

$2,069,209
Jau-Shyong Shyong Hong · National Institute Of Environmental Health Sciences · ZIA · FY2015 · ES

DETECT-AD: Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease

$2,068,051
Jeffrey A Kaye · Oregon Health & Science University · R56 · FY2022 · AG

DEGENERATIVE AND DEMENTING DISEASES OF AGING

$2,064,323
University Of California San Francisco · P01 · FY2003 · AG

Neuronal ABCA7 loss of function and Alzheimer’s disease

$2,063,098
Takahisa Kanekiyo · Mayo Clinic Jacksonville · RF1 · FY2023 · AG

Cellular mechanisms of neuronal dysfunction in addiction and neurodegeneration

$2,062,691
Brandon Harvey · National Institute On Drug Abuse · ZIA · FY2023 · DA

Large-Scale Genomic Analysis of Aging-Related Cognitive Change Prior to Dementia Onset

$2,060,713
Elliot Max Tucker-Drob · University Of Texas At Austin · RF1 · FY2021 · AG

Cell autonomous and non-cell autonomous roles of the GWAS risk factor BIN1 in Alzheimer's disease neuropathology

$2,060,594
Gopal Thinakaran · University Of Chicago · RF1 · FY2016 · AG

Neuronal Mechanisms of Copper Transport and Toxicity

$2,058,365
Victor Faundez · Emory University · RF1 · FY2018 · AG

ASYMMETRIC NEURODEGENERATION AND LANGUAGE IN PRIMARY PROGRESSIVE APHASIA

$2,058,335
Marek-Marsel M Mesulam · Northwestern University At Chicago · R01 · FY2025 · AG

ASYMMETRIC NEURODEGENERATION AND LANGUAGE IN PRIMARY PROGRESSIVE APHASIA

$2,057,942
Marek-Marsel M Mesulam · Northwestern University At Chicago · R01 · FY2023 · AG

CAA, Tau and Neurodegeneration

$2,053,963
Cristian Lasagna-Reeves · Baylor College Of Medicine · RF1 · FY2024 · AG